KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

• Published in: Leukemia research Vol. 50; pp. 123 - 131
• Main Authors: Swords, Ronan T., MD, PhD, FRCPI, FRCPath, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, MRCS, LRCP, FRCP, FRCPath, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, FRACP, FRCPA, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2016
• Subjects: Acute myeloid leukemia; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Drug Administration Schedule; EphA3; Ephrin receptor tyrosine kinase; Female; Hematologic Neoplasms - drug therapy; Hematology, Oncology and Palliative Medicine; Humans; Infusions, Intravenous; KB004; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic syndromes; Myelofibrosis; Protein Kinase Inhibitors - therapeutic use; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Salvage Therapy; Treatment Outcome; KB004; Myelofibrosis; Acute myeloid leukemia; Myelodysplastic syndromes; Ephrin receptor tyrosine kinase; EphA3
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2016.09.012

Highlights • KB004 is a novel anti-ephrin novel monoclonal antibody targeting EphA3. • KB004 was safe and relatively well-tolerated in patients with myeloid neoplasms. • Manageable infusion reactions were dose limiting. • There was clinical activity in patients with fibrotic MDS and myelofibrosis.